| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825456 | Clinical Therapeutics | 2013 | 7 Pages |
Abstract
Suspect online NTI drug access from no prescription vendors represents a significant patient safety risk because of potential patient drug switching and risk of counterfeit versions. Further, state health care exchanges with coverage limitations may drive patients to seek formulations online. Food and Drug Administration harmonization with tighter international NTI drug standards should be considered, and aggressive action against suspect online marketers should be a regulatory and public health priority.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Bryan A. MD, PhD, JD, Tim K. MAS, Kimberly M. MD,